A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea
- Registration Number
- NCT00667173
- Lead Sponsor
- Dow Pharmaceutical Sciences
- Brief Summary
The purpose of this study is to assess the safety and effectiveness of IDP-115 in treating patients with rosacea.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
- Presence of facial rosacea
- Presence of inflammatory lesions
Exclusion Criteria
- Dermatological conditions of the face that could interfere with clinical evaluations
- Known history of photosensitivity disorders (such as lupus erythematosus or polymorphous light eruption)
- Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 IDP-115 - 2 Vehicle - 3 Vehicle -
- Primary Outcome Measures
Name Time Method Change from baseline in the number of inflammatory lesions 12 weeks Improvement from baseline in global severity 12 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in erythema 12 weeks
Trial Locations
- Locations (10)
University Dermatology Consultants, Inc.
🇺🇸Cincinnati, Ohio, United States
Medical Affiliated Research Center, Inc.
🇺🇸Huntsville, Alabama, United States
Therapeutics Clinical Research
🇺🇸San Diego, California, United States
Solano Clinical Research
🇺🇸Vallejo, California, United States
FXM Research Corp.
🇺🇸Miami, Florida, United States
MedaPhase Inc.
🇺🇸Newnan, Georgia, United States
Henry Ford Medical Center
🇺🇸Detroit, Michigan, United States
Academic Dermatology Associates
🇺🇸Albuquerque, New Mexico, United States
DermResearch, Inc.
🇺🇸Austin, Texas, United States
Cherry Creek Dermatology Research Inc.
🇺🇸Denver,, Colorado, United States